Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	14.72B -11.6%
Revenue (ttm)	6.68B +11.4%
Net Income	827.17M +14.0%
EPS	1.53 +8.6%
Shares Out	541.12M
PE Ratio	17.80
Forward PE	n/a
Dividend	0.79 (2.89%)
Ex-Dividend Date	Jul 17, 2026

Volume	1,544,549
Open	26.50
Previous Close	27.75
Day's Range	26.40 - 27.40
52-Week Range	26.60 - 31.49
Beta	0.00
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error